The Bull Case For Southwest Airlines (LUV) Could Change Following Premium Seating and St. Thomas Expansion News

• Earlier this month, Southwest Airlines announced plans to expand its network in 2026 by launching new service at St. Thomas in the U.S. Virgin Islands, along with introducing assigned and premium seating, updated fare bundles, and a reconfigured fleet.
• The addition of St. Thomas marks the carrier’s ninth island destination in the Atlantic Basin, underlining Southwest’s continued focus on growth in leisure-oriented markets and enhanced onboard products.
• We’ll explore how the St. Thomas route launch and premium seating announcements may influence Southwest’s longer-term investment narrative.

Outshine the giants: these 19 early-stage AI stocks could fund your retirement.

Southwest Airlines Investment Narrative Recap

To be a Southwest Airlines shareholder, you typically need to believe that ongoing efforts to grow leisure travel markets and enhance customer offerings can offset challenges in a competitive, uncertain industry. The announcement of new service to St. Thomas and upgraded seating options reflects Southwest’s commitment to driving demand and capturing higher-yield customers, but these changes do not materially alter the biggest short-term catalyst: successful implementation of differentiated fare and seating products. The largest risk remains sensitivity to leisure travel demand, particularly given fluctuating consumer trends.

The introduction of assigned and premium seating, set for rollout in the third quarter of 2025, is especially relevant alongside the St. Thomas network expansion. This initiative aligns with the critical near-term goal of boosting unit revenue through product segmentation, as the company seeks to attract a wider customer base and generate higher margins per seat, while adjusting to evolving consumer preferences and competitive pressure.

In contrast to the momentum from route and product launches, investors should be aware of the ongoing risk that...

Read the full narrative on Southwest Airlines (it's free!)

Southwest Airlines' outlook anticipates $32.2 billion in revenue and $1.9 billion in earnings by 2028. Achieving this would require revenue growth of 5.2% per year and an earnings increase of about $1.35 billion from the current $547.0 million.

Uncover how Southwest Airlines' forecasts yield a $28.39 fair value, a 23% downside to its current price.

Exploring Other Perspectives

Eight fair value estimates from the Simply Wall St Community range from US$1.31 to US$42 per share, underscoring very different outlooks among retail investors. While opinions are split, the company’s performance still depends heavily on how new premium products influence both revenues and consumer loyalty, explore these contrasting viewpoints to inform your perspective.

Explore 8 other fair value estimates on Southwest Airlines - why the stock might be worth as much as 14% more than the current price!

Build Your Own Southwest Airlines Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Southwest Airlines research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Southwest Airlines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Southwest Airlines' overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• The end of cancer? These 25 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com